CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors

Abken, 2017, Driving CARs on the highway to solid cancer: some considerations on the adoptive therapy with CAR T cells, Hum. Gene Ther., 28, 1047, 10.1089/hum.2017.115

Ahmed, 2015, Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma, J. Clin. Oncol., 33, 1688, 10.1200/JCO.2014.58.0225

Baskic, 2014, Evaluation of inflammatory biomarkers as helping diagnostic tool in patients with breast cancer, Cancer Biomark., 14, 401, 10.3233/CBM-140426

Bayhan, 2014, Serum cytokine levels in patients with colorectal cancers according to tumor stages and VEGF gene polymorphism, Hepatogastroenterology, 61, 1889

Broz, 2014, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity, Cancer Cell, 26, 638, 10.1016/j.ccell.2014.09.007

Cao, 1999, Interleukin-18 acts as an angiogenesis and tumor suppressor, FASEB J., 13, 2195, 10.1096/fasebj.13.15.2195

Carbone, 2009, IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival, J. Immunother., 32, 920, 10.1097/CJI.0b013e3181b29168

Chaix, 2008, Cutting edge: Priming of NK cells by IL-18, J. Immunol., 181, 1627, 10.4049/jimmunol.181.3.1627

Chen, 2012, Interleukin-18 and -12 synergistically enhance cytotoxic functions of tumor-infiltrating lymphocytes, Chin. Med. J. (Engl.), 125, 4245

Chmielewski, 2015, TRUCKs: the fourth generation of CARs, Expert Opin. Biol. Ther., 15, 1145, 10.1517/14712598.2015.1046430

Chmielewski, 2012, T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice, Gastroenterology, 143, 10.1053/j.gastro.2012.06.037

Chmielewski, 2013, T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term, Gene Ther., 20, 177, 10.1038/gt.2012.21

Dinarello, 2006, The paradox of pro-inflammatory cytokines in cancer, Cancer Metastasis Rev., 25, 307, 10.1007/s10555-006-9000-8

Eades-Perner, 1994, Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern, Cancer Res., 54, 4169

Feng, 2016, Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer, Sci. China Life Sci., 59, 468, 10.1007/s11427-016-5023-8

Ghoneim, 2017, De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation, Cell, 170, 142, 10.1016/j.cell.2017.06.007

Guo, 2016, Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer, Clin. Cancer Res., 22, 5939, 10.1158/1078-0432.CCR-15-1144

Hoffmann, 2001, Fusion proteins of B7.1 and a carcinoembryonic antigen (CEA)-specific antibody fragment opsonize CEA-expressing tumor cells and coactivate T-cell immunity, Int. J. Cancer, 92, 725, 10.1002/1097-0215(20010601)92:5<725::AID-IJC1252>3.0.CO;2-S

Holzinger, 2016, The growing world of CAR T cell trials: a systematic review, Cancer Immunol. Immunother., 65, 1433, 10.1007/s00262-016-1895-5

Hu, 2017, Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18, Cell Rep., 20, 3025, 10.1016/j.celrep.2017.09.002

John, 2014, Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor, Methods Mol. Biol., 1139, 177, 10.1007/978-1-4939-0345-0_16

Ma, 2016, Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18, Clin. Cancer Res., 22, 2969, 10.1158/1078-0432.CCR-15-1655

Markowitz, 2016, Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes, Cancer Res., 76, 2394, 10.1158/0008-5472.CAN-15-1548

Maus, 2016, Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy, Clin. Cancer Res., 22, 1875, 10.1158/1078-0432.CCR-15-1433

Nelson, 2015, Novel immunotherapies for hematologic malignancies, Immunol. Rev., 263, 90, 10.1111/imr.12245

O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci. Transl. Med, 9, eaaa0984, 10.1126/scitranslmed.aaa0984

Okamoto, 1999, Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12, J. Immunol., 162, 3202, 10.4049/jimmunol.162.6.3202

Pasero, 2013, Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity, Immunol. Lett., 151, 71, 10.1016/j.imlet.2013.01.008

Rao, 2012, Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation, Immunity, 36, 374, 10.1016/j.immuni.2012.01.015

Robertson, 2008, A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer, Clin. Cancer Res., 14, 3462, 10.1158/1078-0432.CCR-07-4740

Schneider, 2006, Enhanced expression of interleukin-18 in serum and pancreas of patients with chronic pancreatitis, World J. Gastroenterol., 12, 6507, 10.3748/wjg.v12.i40.6507

Schwartzberg, 2002, Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin, Clin. Cancer Res., 8, 2488

Śledzińska, 2015, Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy, Mol. Oncol., 9, 1936, 10.1016/j.molonc.2015.10.008

Staron, 2014, The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection, Immunity, 41, 802, 10.1016/j.immuni.2014.10.013

Tas, 2015, Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer, Biomed. Pharmacother., 70, 19, 10.1016/j.biopha.2014.12.040

Terme, 2011, IL-18 induces PD-1-dependent immunosuppression in cancer, Cancer Res., 71, 5393, 10.1158/0008-5472.CAN-11-0993

Tsutsumi, 2014, The structural basis for receptor recognition of human interleukin-18, Nat. Commun., 5, 5340, 10.1038/ncomms6340

Utzschneider, 2013, T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion, Nat. Immunol., 14, 603, 10.1038/ni.2606

Vidal-Vanaclocha, 2006, Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression, Cancer Metastasis Rev., 25, 417, 10.1007/s10555-006-9013-3

Vukmanovic-Stejic, 2000, Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes, Blood, 95, 231, 10.1182/blood.V95.1.231

Wong, 2013, IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment, Cancer Res., 73, 4653, 10.1158/0008-5472.CAN-12-4366

Zhang, 2016, Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a Foxo1-dependent manner, Cell Rep., 14, 1206, 10.1016/j.celrep.2015.12.095

Zhang, 2017, Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers, Mol. Ther., 25, 1248, 10.1016/j.ymthe.2017.03.010

Zhu, 2010, T-bet and eomesodermin are required for T cell-mediated antitumor immune responses, J. Immunol., 185, 3174, 10.4049/jimmunol.1000749